Search

Your search keyword '"Gianluca Amato"' showing total 109 results
Start Over Author "Gianluca Amato"
109 results on '"Gianluca Amato"'

1. JGMP: Java bindings and wrappers for the GMP library

Author

Gianluca Amato and Francesca Scozzari

Subjects
Arbitrary precision arithmetic, Integer numbers, Rational numbers, Floating point numbers, Java, Computer software, QA76.75-76.765
Abstract

The GNU Multiple Precision Arithmetic Library (GMP) is a widely used library for computing with arbitrary precision arithmetic. The library has functionally complete bindings for many programming languages, including .NET, C++, OCaml, Python, Ruby, and Rust, with the notable exception of Java. The JGMP library provides Java bindings and wrappers for using GMP from within any JVM-based language. The library has been thoroughly tested and benchmarked.

Published
2023
Full Text
View/download PDF

2. AI for Sustainability: Research at Ud'A Node.

Author

Gianluca Amato, Alessia Amelio, Luciano Caroprese, Piero Chiacchiaretta, Fabio Fioravanti, Luigi Ippoliti, Maria Chiara Meo, Gianpiero Monaco, Christian Morbidoni, Luca Moscardelli, Maurizio Parton, and Francesca Scozzari

Published
2024

4. Intranasal 'painless' human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice.

Author

Simona Capsoni, Sara Marinelli, Marcello Ceci, Domenico Vignone, Gianluca Amato, Francesca Malerba, Francesca Paoletti, Giovanni Meli, Alessandro Viegi, Flaminia Pavone, and Antonino Cattaneo

Subjects
Medicine, Science
Abstract

Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer's disease (AD) treatment but the clinical application is hindered by its potent pro-nociceptive activity. Thus, to reduce systemic exposure that would induce pain, in recent clinical studies NGF was administered through an invasive intracerebral gene-therapy approach. Our group demonstrated the feasibility of a non-invasive intranasal delivery of NGF in a mouse model of neurodegeneration. NGF therapeutic window could be further increased if its nociceptive effects could be avoided altogether. In this study we exploit forms of NGF, mutated at residue R100, inspired by the human genetic disease HSAN V (Hereditary Sensory Autonomic Neuropathy Type V), which would allow increasing the dose of NGF without triggering pain. We show that "painless" hNGF displays full neurotrophic and anti-amyloidogenic activities in neuronal cultures, and a reduced nociceptive activity in vivo. When administered intranasally to APPxPS1 mice ( n = 8), hNGFP61S/R100E prevents the progress of neurodegeneration and of behavioral deficits. These results demonstrate the in vivo neuroprotective and anti-amyloidogenic properties of hNGFR100 mutants and provide a rational basis for the development of "painless" hNGF variants as a new generation of therapeutics for neurodegenerative diseases.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results